UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 25, 2013
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter)
Delaware | 0-5286 | 38-0715562 | |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | |
2700 West Front Street Statesville, North Carolina (Address of principal executive offices) |
28677 (Zip Code)
|
Registrant’s telephone number, including area code 704-873-7202
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On June 25, 2013, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and year ended April 30, 2013. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No. | |
99.1 | Press Release of Kewaunee Scientific Corporation dated June 25, 2013 |
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant) | |||
Kewaunee Scientific Corporation | |||
Date: June 25, 2013 | /s/ D. Michael Parker | ||
D. Michael Parker Senior Vice President, Finance | |||
Chief Financial Officer |
Kewaunee Scientific Reports Record Sales for Year and Fourth Quarter
STATESVILLE, N.C., June 25, 2013 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and year ended April 30, 2013.
Fiscal Year 2013 Results
Sales for the year were a record $117,121,000, up 13.9% from sales of $102,847,000 in the prior year. Net earnings for the year were $3,044,000, or $1.17 per diluted share, up from net earnings of $1,031,000, or $0.40 per diluted share, in the prior year. Earnings for the year were favorably impacted by the increase in sales, strong earnings from domestic operations, and reduced manufacturing, overhead, and administrative costs.
Sales from domestic operations for the year were $93,519,000, up 11.4% from sales of $83,971,000 in the prior year. The marketplace for private sector laboratory construction projects held up well during the year, as increased activity for mid-sized projects more than offset fewer large projects. The marketplace for publicly funded wood educational projects continued to be well below pre-recession levels, with fewer large project opportunities available during the year. The Company continued to successfully win projects and increase market share in most of its geographic markets, although pricing remained very competitive.
Sales from international operations for the year were $23,602,000, up 25.0% from sales of $18,876,000 in the prior year. The increase resulted as several large international orders from prior periods were manufactured and shipped during the year. The Company continues to have a strong backlog of international orders and to see good opportunities for growth in its international markets.
The order backlog was $80.2 million at April 30, 2013, as compared to $86.2 million at April 30, 2012. The change in the backlog reflects the manufacturing and shipping of a large international order during the year, which was partially offset by a small increase in the domestic order backlog.
Fourth
Quarter Results
Sales for the fourth quarter were a record $31,803,000, up 9.7% from sales of $28,990,000 in the same period of the prior year. Sales from domestic operations were $24,762,000, up 26.3% over sales of $19,607,000 in the prior year. Sales from international operations were $7,041,000, a decline of 25.0% from sales of $9,383,000 in the same period of the prior year.
Net earnings for the quarter were $1,217,000, or $0.46 per diluted share, as compared to earnings of $1,256,000, or $0.49 per diluted share, in the same period of the prior year. Earnings for the quarter were favorably impacted by the increase in sales, very strong earnings from domestic operations, and reduced manufacturing, overhead, and administrative costs. Sales and earnings from international operations were below the same period last year, as the last year period was boosted by the manufacturing and shipping of several large international orders.
The Company's balance sheet and financial condition remain strong. Cash on hand at the end of the year was $6.5 million and working capital was $25.1 million. Short term borrowings under the Company's $15 million revolver line of credit were $7.0 million and term debt outstanding was $3.5 million. The debt-to-equity ratio at year end was .33-to-1.
"Fiscal year 2013 was an excellent year," said William A. Shumaker, Kewaunee's Chief Executive Officer. "I am pleased that we exceeded our sales and earnings goals and made excellent progress against our goals to strengthen the Kewaunee brand, strengthen relationships with existing customers, build relationships with new and prospective customers, reduce costs, and increase market share. The progress in all of these areas not only resulted in record sales for the fourth quarter and year, but it provides momentum as we enter the new year.
"As I look forward to fiscal year 2014, I expect progress to continue in all of the above areas. Although my retirement will take me out of the day-to-day operations of the Company as of the end of this month, I have the utmost confidence in the members of the management team, each of whom has many years of valuable experience in the laboratory furniture industry."
Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.
The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets. One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at http://www.kewaunee.com.
Certain statements in this release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices.
Kewaunee Scientific Corporation | ||||||||
Consolidated Statements of Operations | ||||||||
(in thousands, except per share data) | ||||||||
|
| Three months ended |
| Years ended | ||||
|
| April 30, |
| April 30, | ||||
|
| 2013 |
| 2012 |
| 2013 |
| 2012 |
|
| (Unaudited) |
|
|
|
| ||
Net sales |
| $ 31,803 |
| $ 28,990 |
| $ 117,121 |
| $ 102,847 |
Cost of products sold |
| 25,024 |
| 21,638 |
| 94,863 |
| 83,691 |
Gross profit |
| 6,779 |
| 7,352 |
| 22,258 |
| 19,156 |
Operating expenses |
| 4,776 |
| 4,493 |
| 16,981 |
| 16,443 |
Operating earnings |
| 2,003 |
| 2,859 |
| 5,277 |
| 2,713 |
Other income |
| 46 |
| 43 |
| 306 |
| 271 |
Interest expense |
| (67) |
| (112) |
| (362) |
| (445) |
Earnings before income taxes |
| 1,982 |
| 2,790 |
| 5,221 |
| 2,539 |
Income tax expense |
| 578 |
| 976 |
| 1,540 |
| 739 |
Net earnings |
| 1,404 |
| 1,814 |
| 3,681 |
| 1,800 |
Less: net earnings attributable to |
|
|
|
|
|
|
|
|
the noncontrolling interest |
| 187 |
| 558 |
| 637 |
| 769 |
Net earnings attributable to
|
| $ 1,217 |
| $ 1,256 |
| $ 3,044 |
| $ 1,031 |
|
|
|
|
|
|
|
|
|
Net earnings per share attributable to
|
|
|
|
|
|
|
|
|
Basic |
| $ 0.47 |
| $ 0.49 |
| $ 1.18 |
| $ 0.40 |
Diluted |
| $ 0.46 |
| $ 0.49 |
| $ 1.17 |
| $ 0.40 |
|
|
|
|
|
|
|
|
|
Weighted average number of common |
|
|
|
|
|
|
|
|
shares outstanding |
|
|
|
|
|
|
|
|
Basic |
| 2,591 |
| 2,579 |
| 2,587 |
| 2,579 |
Diluted |
| 2,613 |
| 2,580 |
| 2,600 |
| 2,580 |
|
|
|
|
|
|
|
|
|
Kewaunee Scientific Corporation |
|
| ||||||
Condensed Consolidated Balance Sheets |
|
| ||||||
(in thousands) |
|
| ||||||
|
|
|
| April 30, |
| April 30, |
|
|
|
|
|
| 2013 |
| 2012 |
|
|
Assets |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ 5,811 |
| $ 6,188 |
|
| ||
Restricted Cash |
| 691 |
| 704 |
|
| ||
Receivables, less allowances |
| 25,884 |
| 22,469 |
|
| ||
Inventories |
| 13,203 |
| 11,760 |
|
| ||
Prepaid expenses and other current assets |
| 1,641 |
| 1,702 |
|
| ||
Total Current Assets |
| 47,230 |
| 42,823 |
|
| ||
Net property, plant and equipment |
| 15,098 |
| 15,346 |
|
| ||
Other assets |
| 6,414 |
| 5,192 |
|
| ||
Total Assets |
| $ 68,742 |
| $ 63,361 |
|
| ||
|
|
|
|
|
|
|
|
|
Liabilities and Equity |
|
|
|
|
|
| ||
Short-term borrowings |
| $ 6,997 |
| $ 6,816 |
|
| ||
Current obligations under capital leases and long-term debt |
| 200 |
| 236 |
|
| ||
Accounts payable |
| 10,406 |
| 8,848 |
|
| ||
Other current liabilities |
| 4,512 |
| 3,565 |
|
| ||
Total Current Liabilities |
| 22,115 |
| 19,465 |
|
| ||
Other non-current liabilities |
| 12,934 |
| 12,238 |
|
| ||
Total Liabilities |
| 35,049 |
| 31,703 |
|
| ||
Noncontrolling interest |
| 2,017 |
| 2,147 |
|
| ||
Kewaunee Scientific Corporation equity |
| 31,676 |
| 29,511 |
|
| ||
Total Equity |
| 33,693 |
| 31,658 |
|
| ||
Total Liabilities and Stockholders' Equity |
| $ 68,742 |
| $ 63,361 |
|
|
Contact: | D. Michael Parker |
| 704/871-3290 |